問卷

TPIDB > Principal Investigator

Principal Investigator


Taipei Veterans General Hospital

Division of Obstetrics & Gynecology

更新時間:2024-02-21

楊思婷
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

11Cases

2025-11-01 - 2033-12-31

Phase III

Active
A Phase 3, Multicenter, Randomized, Open-label Trial of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy With or Without Radiotherapy as Adjuvant Treatment for HER2-Expressing (IHC 3+/2+) Endometrial Cancer (DESTINY-Endometrial02/ GOG-3122/ ENGOT-en30/GINECO)
  • Condition/Disease

    Endometrial Cancer

  • Test Drug

    Cryocrystalline injection Intravenous infusion Intravenous infusion Intravenous infusion Intravenous infusion

Participate Sites
5Sites

Not yet recruiting5Sites

2024-08-15 - 2026-12-31

Others

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Not yet recruiting5Sites

Recruiting4Sites

2023-07-01 - 2030-02-28

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Not yet recruiting1Sites

Recruiting10Sites

2026-05-15 - 2028-04-30

Phase I

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2025-11-19 - 2030-06-30

Phase II

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2024-04-01 - 2029-12-31

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2024-12-01 - 2028-12-31

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2026-05-01 - 2029-12-31

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2025-07-10 - 2029-08-30

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2025-03-01 - 2032-01-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

1 2